DPFMDA: Distributed and privatized framework for miRNA-Disease association prediction

Abstract In this paper, we developed a novel distributed and privatized framework for miRNA-disease association prediction (DPFMDA) to predict potential miRNA-disease associations. DPFMDA assumes that diseases and miRNAs can be represented as feature matrices. Through independent factorization, collaborative analysis and matrix re-factorization, feature matrices are estimated and potential associations in miRNA-disease association matrix are predicted. The proposed computational model is tested and verified by leave-one-out cross validation (LOOCV). The AUCs of global and local LOOCV are 0.8859 and 0.8267 respectively, which outperform the state-of-the-art computational models. DPFMDA is further evaluated with case studies of four important human complex diseases. We test Esophageal Neoplasms and Prostate Neoplasms using DPFMDA in the HMDD v2.0 database. For Breast Neoplasms, we use the HMDD v2.0 database which removes all the known miRNAs-disease associations on Breast Neoplasms. For Hepatocellular Carcinoma, HMDD v1.0 database is used as the input of DPFMDA and predicted results are verified with HMDD v2.0, dbDEMC and miR2Disease databases. The results show that 90% (Esophageal Neoplasms), 88% (Prostate Neoplasms), 98% (Breast Neoplasms) and 86% (Hepatocellular Carcinoma) of top 50 predicted miRNA-disease associations are confirmed by recent experimental studies respectively. It is anticipated that DPFMDA would be an effective and extensible method for potential miRNA-disease association prediction.

[1]  Yadong Wang,et al.  Prioritization of disease microRNAs through a human phenome-microRNAome network , 2010, BMC Systems Biology.

[2]  N. Zhou,et al.  miRNA-10b sponge: An anti-breast cancer study in vitro , 2016, Oncology reports.

[3]  Peizhang Xu,et al.  MicroRNAs and the regulation of cell death. , 2004, Trends in genetics : TIG.

[4]  Guoqiang Zhao,et al.  miRNA-1207-5p is associated with cancer progression by targeting stomatin-like protein 2 in esophageal carcinoma. , 2015, International journal of oncology.

[5]  Xing Chen,et al.  Semi-supervised learning for potential human microRNA-disease associations inference , 2014, Scientific Reports.

[6]  Yadong Wang,et al.  miR2Disease: a manually curated database for microRNA deregulation in human disease , 2008, Nucleic Acids Res..

[7]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Tomohiko Ichikawa,et al.  Functional significance of aberrantly expressed microRNAs in prostate cancer , 2015, International journal of urology : official journal of the Japanese Urological Association.

[9]  T. Tuschl,et al.  Mechanisms of gene silencing by double-stranded RNA , 2004, Nature.

[10]  Q. Cui,et al.  An Analysis of Human MicroRNA and Disease Associations , 2008, PloS one.

[11]  K. Kelnar,et al.  The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. , 2011, Nature medicine.

[12]  Yun Xiao,et al.  Prioritizing Candidate Disease miRNAs by Topological Features in the miRNA Target–Dysregulated Network: Case Study of Prostate Cancer , 2011, Molecular Cancer Therapeutics.

[13]  Jan Gorodkin,et al.  Protein-driven inference of miRNA–disease associations , 2013, Bioinform..

[14]  Guoqiang Zhao,et al.  miRNA-1207-5p is associated with cancer progression by targeting stomatin-like protein 2 in esophageal carcinoma , 2015, International journal of oncology.

[15]  Hsien-Da Huang,et al.  MicroRNA‐122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma , 2009, Hepatology.

[16]  Changning Liu,et al.  dbDEMC: a database of differentially expressed miRNAs in human cancers , 2010, BMC Genomics.

[17]  Dan Li,et al.  miRNA-337-3p inhibits gastric cancer progression through repressing myeloid zinc finger 1-facilitated expression of matrix metalloproteinase 14 , 2016, Oncotarget.

[18]  Yang Li,et al.  HMDD v2.0: a database for experimentally supported human microRNA and disease associations , 2013, Nucleic Acids Res..

[19]  Xing Chen,et al.  RWRMDA: predicting novel human microRNA-disease associations. , 2012, Molecular bioSystems.

[20]  Lijun Xu,et al.  miR‐150 promotes the proliferation of lung cancer cells by targeting P53 , 2013, FEBS letters.

[21]  Leigh-Ann MacFarlane,et al.  MicroRNA: Biogenesis, Function and Role in Cancer , 2010, Current genomics.

[22]  Chen Chen,et al.  MicroRNAs in esophageal cancer (review). , 2012, Molecular medicine reports.

[23]  M. Byrom,et al.  Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis , 2005, Nucleic acids research.

[24]  P. Bork,et al.  G2D: a tool for mining genes associated with disease , 2005, BMC Genetics.

[25]  A. Stewart,et al.  Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. , 2000, Journal of the American College of Surgeons.

[26]  Fang-Ming Deng,et al.  MicroRNAs as predictive biomarkers and therapeutic targets in prostate cancer. , 2014, American journal of clinical and experimental urology.

[27]  Qionghai Dai,et al.  WBSMDA: Within and Between Score for MiRNA-Disease Association prediction , 2016, Scientific Reports.